Clinical Trial Update: Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating miravirsen in combination with telaprevir and ribavirin in null responders to pegylated interferon plus ribavirin for chronic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Miravirsen (miravirsen)
• Ribavirin (ribavirin)
• Telaprevir (telaprevir)

Snippet

Sponsor: Santaris Pharma A/S | Conditions: Hepatitis C, Chronic | Phase 2 | Status: UNKNOWN